Pendulum: Revolutionizing gut health through science and innovation
Clinically-studied, proprietary strains designed to transform health through the gut microbiome.*
.png%3F2025-10-07T18%3A22%3A25.841Z&w=3840&q=100)
Reimagine the health of your patients by targeting the gut microbiome
Using cutting-edge technology and microbiome science, Pendulum was the first company in the US to market live Akkermansia muciniphila. Akkermansia supports the synthesis of health-promoting postbioitics and strengthens gut barrier integrity.*
Pendulum’s Akkermansia-containing formulations have been clinically studied and published in the British Medical Journal. Improving gut barrier function and maintaining healthy blood sugar levels with Pendulum’s strains is a foundational way to help your patients find optimal health by harnessing the power of the gut microbiome.*
.jpg%3F2025-10-07T18%3A35%3A23.016Z&w=3840&q=100)
Join the 15,000+ practitioners recommending Pendulum Akkermansia
Akkermansia 100 Pro
Maintain keystone strain levels Regular strength live Akkermansia muciniphila helps maintain gut health, supports the gut lining, and manages gut permeability.*
Akkermansia 500 Pro
Replenish keystone strain levels Maximum strength live Akkermansia muciniphila—ideal for patients with advanced indications of intestinal barrier permeability, replenishing this critical strain for optimal gut health.^*
Get to know the products
Fullscript and Pendulum provider survey with Akkermansia 500 Pro
Will continue to recommend Akkermansia 500 Pro**
Would recommend Akkermansia 500 Pro to other health care providers**
Study
How providers are using a GLP-1 probiotic in clinical practice
In survey conducted in 2024 of healthcare providers who use a GLP-1 Probiotic
- 97% of healthcare providers recommend as a way to manage food cravings+
- 78% Recommend as a strategy to help patients transition off of GLP-1 medications, specifically to help manage food cravings associated with this transition+
- 64% Recommend as a first line approach before prescribing a GLP-1 medication+
- 53% Recommend in combination with GLP-1 medications+
Webinar
Hacking the popular satiety hormone through the microbiome with Pendulum and Fullscript
Colleen Cutcliffe
Pendulum CEO
Dr. Jeff Gladd, MD
Chief Medical Officer at Fullscript
Dr. Alex Keller, ND
Medical Director at Fullscript
Join Fullscript’s Chief Medical Officer, Jeff Gladd, MD, and Medical Director, Alex Keller, ND, as they discuss novel microbiome interventions with Pendulum’s Chief Executive Officer, Colleen Cutcliffe, Ph.D.
.png%3F2025-10-07T18%3A46%3A47.222Z&w=3840&q=100)
Resources for your practice
Fullscript accounts are $0/month — for everyone
Get your practice and patients up and running quickly at no cost.
^ Based on preclinical studies
1, 2 Based on a multicenter, double-blind, randomized placebo-controlled trial
3 Improvements to postprandial glucose control in subjects with type 2 diabetes: a multicenter, double blind, randomized placebo-controlled trial of a novel probiotic formulation, Fanny Perraudeau et al, https://drc.bmj.com/content/8/1/e001319
**Survey results from 82 providers who recommended or purchased Akkermansia 500 million AFU between January-July 2024 on Fullscript.
+Based on a survey conducted internally in 2024 of 64 healthcare providers
.png%3F2025-10-07T18%3A46%3A20.794Z&w=3840&q=100)
